- Home
- LITS vs THAR Comparison
LITS vs THAR Comparison
Compare LITS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITS
- THAR
- Stock Information
- Founded
- LITS 2000
- THAR 2017
- Country
- LITS United States
- THAR United States
- Employees
- LITS N/A
- THAR N/A
- Industry
- LITS Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- LITS Health Care
- THAR Health Care
- Exchange
- LITS Nasdaq
- THAR Nasdaq
- Market Cap
- LITS 96.2M
- THAR 85.9M
- IPO Year
- LITS N/A
- THAR 2022
- Fundamental
- Price
- LITS $1.85
- THAR $2.58
- Analyst Decision
- LITS
- THAR Strong Buy
- Analyst Count
- LITS 0
- THAR 1
- Target Price
- LITS N/A
- THAR $17.00
- AVG Volume (30 Days)
- LITS 539.5K
- THAR 3.5M
- Earning Date
- LITS 11-17-2025
- THAR 11-12-2025
- Dividend Yield
- LITS N/A
- THAR N/A
- EPS Growth
- LITS N/A
- THAR N/A
- EPS
- LITS N/A
- THAR N/A
- Revenue
- LITS N/A
- THAR N/A
- Revenue This Year
- LITS N/A
- THAR N/A
- Revenue Next Year
- LITS N/A
- THAR N/A
- P/E Ratio
- LITS N/A
- THAR N/A
- Revenue Growth
- LITS N/A
- THAR N/A
- 52 Week Low
- LITS $1.46
- THAR $0.95
- 52 Week High
- LITS $9.00
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- LITS N/A
- THAR 42.29
- Support Level
- LITS N/A
- THAR $2.35
- Resistance Level
- LITS N/A
- THAR $2.55
- Average True Range (ATR)
- LITS 0.00
- THAR 0.31
- MACD
- LITS 0.00
- THAR -0.06
- Stochastic Oscillator
- LITS 0.00
- THAR 19.03
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.